Alternative methods in toxicology: pre-validated and validated methods.

The development of alternative methods to animal experimentation has progressed rapidly over the last 20 years. Today, in vitro and in silico methods have an important role in the hazard identification and assessment of toxicology profile of compounds. Advanced alternative methods and their combinations are also used for safety assessment of final products. Several alternative methods, which were scientifically validated and accepted by competent regulatory bodies, can be used for regulatory toxicology purposes, thus reducing or fully replacing living animals in toxicology experimentation. The acceptance of the alternative methods as valuable tools of modern toxicology has been recognized by regulators, including OECD, FDA and EPA.This paper provides a brief overview of the topic "alternative methods in toxicology" and focuses on pre-validated and validated alternative methods and their position in the modern toxicology.

Centre for Alternatives to Animal Testing

European Centre For Validation of Alternative Methods

Environmental Protection Agency

ECVAM′s Scientific Advisory Committee

Food and Drug Administration

Fund for the Replacement of Animals in Medical Experiments

Guidance Document

Interagency Coordinating Committee on the Validation of Alternative Methods

Japanese Center for the Validation of Alternative Methods

Organization for Economic Co-operation and Development

Quantitative structureactivity relationship

Test Guideline

German National Center for Evaluation and Assessment of Alternative methods

Introduction

The development of alternative methods to animal experimentation has progressed rapidly over the last 20 years. Knowledge of alternative methods and their use in planning and conducting toxicology experiments has become essential for modern toxicologists.

Alternative methods (alternative toxicology tests) are methods able to:

reduce the number of animals necessary in a test,

refine toxicology procedures to make them less painful or stressful to laboratory animals, or,

replace animals with non-animal (in vitro, ex-vivo or in silico systems).

These three principles, also known as the “3Rs”, were defined in 1959 by W.M.S. Russell and R.L. Burch in their well-crafted and scientifically valid writing on this subject, “The Principles of Humane Experimental Techniques” (Russell & Burch, 1959).

Reduction is defined as any decrease in the numbers of animals used to obtain information of a given amount and precision; Refinement is defined as any decrease in the incidence or severity of procedures applied to animals; and Replacement is defined as the substitution of conscious living vertebrates by non-sentient material. These three types of alternative procedures are not mutually exclusive; for example, an in vitro test could serve as a partial replacement for an animal test (i.e. it could replace the use of the animal test for certain kinds of test substances, or for a particular type and/or range of toxicological hazard). However, if the in vitro test were used in the context of a tiered testing strategy, it could also serve as a reduction and/or refinement alternative (i.e. it could reduce the number of substances tested in animals, and particularly the number of toxic substances tested) (Russell & Burch, 1959).

The 3Rs provide a strategy for a rational and stepwise approach to minimising animal use and suffering in experiments, without compromising the quality of the scientific work being undertaken. A number of useful alternative methods have been developed for evaluation of the potential toxic effects of chemicals and products since publication of the 3Rs principles. However, it still takes many years to implement these principles into the toxicology praxis. Since 1986, the concept of the 3Rs has been supported by laws in the EU that require researchers and investigators to use available alternatives before conducting in vivo experimentation. The 3Rs Declaration of Bologna, which was adopted in 1999 by the Third World Congress on Alternatives and Animal Use in the Life Sciences, strongly endorsed and reaffirmed the principle of the 3Rs. Today, Reduction, Refinement and Replacement are basic tenets of EU research and other policies concerning the use of animals in scientific testing and experimentation.

The Council Directive 86/609/EEC on the protection of animals used for experimental and scientific purposes in article 7.2 states:

“An experiment shall not be performed if another scientifically satisfactory method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available“.

Article 23 further states:

“The Commission and Member States should encourage research into the development and validation of alternative techniques which could provide the same level of information as that obtained in experiments using animals, but which involve fewer animals or which entail less painful procedures, and shall take such other steps as they consider appropriate to encourage research in this field. The Commission and Member States shall monitor trends inexperimental methods”.

As a response to articles 7 and 23 of the Council Directive 86/609/EEC, the European Centre for the Validation of Alternative Methods (ECVAM) was established in 1991. ECVAM was given the task to scientifically evaluate and validate alternative methods, to serve as an information centre, and to maintain a database on in vitro tests and validated methods. Once a method has undergone a formal validation, an independent peer-review process takes place. Subsequently, the ECVAM Scientific Advisory Committee (ESAC) gives advice on the scientific validity of the method. ECVAM also monitors the research projects funded by the European Commission, and maintains links with relevant platforms and associations devoted to reduction, refinement, and replacement (3Rs of animal use for scientific and regulatory purposes. Recently, two additional committees, PARERE (Network of European Regulators) and ESTAF (Institutions with vested interest in development and use of alternative methods) have been established to help ECVAM in identification of the most promising alternative method with regulatory relevance.

Why do we need to validate alternative methods?

The validation process ensures that alternative methods developed by academic or industrial scientists will be scientifically valid and thus, eventually accepted by regulatory authorities for classification and labeling, product approval or safety testing purposes. Examples of where validated methods are required to generate toxicology data include e.g.:

REACH (Registration, Evaluation, Authorization of Chemicals)

Cosmetic directive 76/768/EEC (VII Amendment)

Classification and Labelling of Chemicals and Transport regulations

Test method validation is a process based on scientifically sound principles by which the reliability and relevance of a particular test, approach, method, or process are established for a specific purpose. Reliability is defined as the extent of reproducibility of results from a test within and among laboratories over time, when performed using the same standardised protocol. Relevance of a test method describes the relationship between the test and the effect in the target species and whether the test method is meaningful and useful for a defined purpose, with the limitations identified. In brief, it is the extent to which the test method correctly measures or predicts the (biological) effect of interest, as appropriate. Regulatory need, usefulness and limitations of the test method are aspects of its relevance. New and updated test methods (both in vivo and in vitro) need to be both reliable and relevant, i.e., validated (Worth & Balls, 2004; Balls et al., 1990a,b).

Validation criteria for new toxicological test methods in use today were developed as collaborative efforts of lead scientists from both the in vivo and in vitro communities, regulators and other experts beginning in the early 1980's. The process was carried out under the auspices of three organizations: the Organisation for Economic Cooperation and Development (OECD), the European Centre for the Validation of Alternative Methods (ECVAM), and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). These international organizations have worked together with external experts and national organizations such as FRAME, ZEBET and CAAT on harmonizing the validation criteria so that there are no major differences between them amongst different countries and continents (Worth & Balls, 2004). Pre-validation and validation principles and criteria for how validation studies of new or updated test methods should be performed are described in detail in the OECD Guidance Document 34 (OECD, 1990).

Typically, there are two types of validation studies, prospective and retrospective validation. A prospective study involves generation of new data while a retrospective study re-assesses existing data. A typical prospective validation process is composed of 6 stages (see Figure 1). A retrospective study is usually limited to the evaluation of data submitted in a standardized and recommended form requested by particular organization performing the evaluation. A test is considered validated when its performance characteristics, advantages, and limitations have been adequately determined for a specific purpose. The measurement of a test's reliability and relevance and required for both types of validation studies.

Figure 1

Scheme of prospective validation study.

Predictive ability and reliability of a test is judged by:

Sensitivity: the percentage of positive chemicals correctly identified.

Specificity: the percentage of negative chemicals correctly identified.

Predictivity: the percentage of predictions for a particular classification, which were correct.

Accuracy: the overall percentage of correct classifications.

Other parameters assessed by the biostatistician during validation are:

Reproducibility within laboratories – concordance of the classifications between 3 and more independent runs in single laboratory.

Reproducibility between laboratories – concordance of the classifications between laboratories.

Probability for correct classification.

Alternative methods and models used for reduction & replacement

The following systems can be used as partial or full replacements of animals in toxicology experiments: i) in vitro methods (primary cultures, finite lifespan cell lines, continuous cell lines, reconstructed 3D tissues), ii) ex vivo methods (isolated animal tissues and organs) and iii) in silico methods: computer simulations and mathematical models, QSAR's etc. Depending on the objective of the study, correctly selected in vitro methods in combination with a deep knowledge of the tested compounds (obtained from databases or computer simulations/QSARs, analytical chemistry, etc.) may be more appropriate for certain areas of interest than their animal counterparts.

Advantages of

controlled testing conditions,

high level of standardisation,

reduction of variability between experiments,

lack of systemic effects,

testing is fast and in most instances inexpensive,

small amount of test material is required,

limited amount of toxic waste is produced,

human cells and tissues can be used,

transgenic cells carrying human genes can be used,

reduction of testing in animals.

Limitations of most

interactions between tissues and organs cannot be tested,

with most in vitro test systems, in vivo dose-responses cannot be obtained for human risk assessment,

systemic effects cannot be evaluated,

pharmacokinetics cannot be evaluated,

chronic effects cannot yet be tested,

technical limitations: solubility, reaction with plastics, lack of in vivo-like barrier properties.

Overview of alternative methods validated and endorsed by ECVAM, ICCVAM, OECD or other regulatory organisations

Once a method has been scientifically validated, it can enter the process of regulatory acceptance and guideline adoption. Regulatory acceptance procedures vary among countries as well as among regulatory agencies within the same country. Therefore, the Organization for Economic Cooperation and Development (OECD) promotes the harmonization of international regulatory acceptance providing the Guidance Document (GD) on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment (OECD, 2005). Adherence to the principles defined in the OECD GD 34 increases the likelihood of the adoption of the a new or modified method.

Table 1 is adopted with minor modification from the AltTox web-site, (www.alttox.org) and provides an overview of the alternative toxicity test methods that are considered valid according to accepted international criteria. The test methods listed in this table have been judged to be scientifically valid by ECVAM, ICCVAM, JaCVAM and the OECD. Although uncommon, a test method may also be accepted for regulatory use without formal validation.

Table 1

Overview of validated/accepted methods (adopted with minor modifications and updates from the AltTox web-site, www.alttox.org).

End-point andMethod Name	Test Type1	Endorsement of Scientific Validity		Regulatory Acceptance
		Lead Authority	Subsequent Endorsement	National/ Regional (for methods not yet accepted internationally)	International acceptance
Acute aquatic toxicity
Upper threshold concentration step-down approach	In vivo	ESAC (2006)
Acute mammalian toxicity (oral)
Acute toxic class method	In vivo		ESAC (2007)		OECD TG 423 (2001)
Fixed dose procedure	In vivo		ESAC (2007)		OECD TG 420 (2001)
Up-and-down procedure	In vivo	ICCVAM (2001)	ESAC (2007)		OECD TG 425 (2006)
Normal human keratinocyte neutral red uptake (NHK NRU) assay	In vitro2	ICCVAM (2006)		US agencies (2008)	Draft OECD TG
Balb/c 3T3 neutral red uptake assay	In vitro2	ICCVAM (2006)		US agencies (2008)	Draft OECD TG
Acute mammalian toxicity (inhalation)
Acute toxic class method	In vivo				OECD TG 436
Fixed concentration procedure	In vivo				Draft TG OECD 433
Chronic toxicity
Ending 1-year dog studies of pesticides	In vivo	ESAC (2006)		Revised US EPA Pesticide Data Requirements
Dermal penetration
In vitro skin absorption methods	In vitro ex-vivo	OECD Expert Group (2002)			OECD TG 428 (2004)
Endocrine mechanistic screens
Androgen receptor binding assay (rat prostate)	In vitro			OPPTS TG 890.1150 (EPA, 2009)
Aromatase inhibition assay (human recombinant)	In vitro			OPPTS TG 890.1200 (EPA, 2009)
ER-alpha transcriptional activation assay for estrogen agnoists3	In vitro				OECD TG 455 (2009)
Estrogen receptor binding assay	In vitro			OPPTS TG 890.1250 (EPA, 2009)
Steroidogenesis (H295R human cell line)	In vitro			OPPTS TG 890.1550 (EPA, 2009)	Draft OECD TG
US EPA Tier 1 Screening Battery	In vitro/In vivo			US EPA (2009)
Eye corrosion
Bovine corneal opacity permeability (BCOP) test	Ex-vivo	ICCVAM (2007)	ESAC (2007) JaCVAM (2009)		OECD TG 437 (2009)
Isolated chicken eye (ICE) test	Ex-vivo	ICCVAM (2007)	ESAC (2007) JaCVAM (2009)		OECD TG 438 (2009)
Hen's egg test-chorioallantoic membrane (HET-CAM)	In vitro/ Ex-vivo			EU Competent Authorities for Dangerous Substances Directive
Isolated rabbit eye test	Ex-vivo			EU Competent Authorities for Dangerous Substances Directive
Eye irritation
Cytosensor Microphysiometer modified (cytotoxicity/cell-function based in vitro assay)	In vitro	ESAC (2009)
Cytotoxicity/cell-function based in vitro assay: Fluorescein Leakage	In vitro	ESAC (2009)
Genotoxicity
Bacterial reverse mutation (Ames) test	In vitro				OECD TG 471 (1997)
In vitro cell gene mutation test	In vitro				OECD TG 476 (1997)
In vitro chromosomal aberration test	In vitro				OECD TG 473 (1997)
In vitro micronucleus test	In vitro	ESAC (2006)			Draft OECD TG 487
In vitro sister chromatid exchange test	In vitro				OECD TG 479 (1986)
In vitro unscheduled DNA synthesis test	In vitro				OECD TG 482 (1986)
Saccharomyces cerevisiae gene mutation assay	In vitro				OECD TG 480 (1986)
Saacharomyces cerevisiae mitotic recombination assay	In vitro				OECD TG 481 (1986)
Hematotoxicity: acute neutropenia
Colony forming unit granulocyte macrophage (CFU-GM) assay	In vitro	ESAC (2006)
Phototoxicity
3T3 Neutral Red Uptake Phototoxicity Test	In vitro	ESAC (1997)			OECD TG 432 (2004)
3T3 NRU Phototoxicity Test: Application to UV filter chemicals	In vitro	ESAC (1998)			OECD TG 432 (2004)
Pyrogenicity
Human whole blood IL-1	In vitro	ESAC (2006)	ICCVAM (2008)4	European Pharmacopeia; US agencies
Human whole blood IL-6	In vitro	ESAC (2006)	ICCVAM (2008)4	European Pharmacopeia; US agencies
Human cryopreserved whole blood IL-1	In vitro	ESAC (2006)	ICCVAM (2008)4	European Pharmacopeia; US agencies
PBMC IL-6	In vitro	ESAC (2006)	ICCVAM (2008)4	European Pharmacopeia; US agencies
MM6 IL-6	In vitro	ESAC (2006)	ICCVAM (2008)4	European Pharmacopeia; US agencies
Limulus amebocyte lysate (LAL) test	In vitro			EDQM/European Pharmacopeia;US Pharmacopeia
Reproductive & developmental toxicity
Embryonic stem cell test	In vitro	ESAC (2002)
Micromass assay	Ex vivo	ESAC (2002)
Whole rat embryo assay	Ex vivo	ESAC (2002)
Skin corrosion
Rat skin transcutaneous electrical resistance (TER)assay	Ex vivo	ESAC (1998)	ICCVAM (2002)		OECD TG 430 (2004)
Corrositex® noncellular membrane	In vitro	ICCVAM (1999)	ESAC (2000)		OECD TG 435 (2006)
EpiSkin® human skin model	In vitro	ESAC (1998)	ICCVAM (2002)		OECD TG 431 (2004)
EpiDermTM human skin model	In vitro	ESAC (1998)	ICCVAM (2002)		OECD TG 431 (2004)
EST-1000 human reconstructed epidermis	In vitro	ESAC (2009)			OECD TG 431 (2004)
SkinEthicTM human skin model	In vitro	ESAC (2006)			OECD TG 431 (2004)
Skin irritation
EpiSkin® skin irritation test	In vitro	ESAC (2007)		EU test method B.46 in COM regulation 440/2008/EC	OECD TG 439 (2010)
EpiDermTM skin irritation test	In vitro	ESAC (2007)5		EU test method B.46 in COM regulation 440/2008/EC
EpiDermTM Modified SIT	In vitro	ESAC (2008)		EU test method B.46 in COM regulation 440/2008/EC	OECD TG 439 (2010)
SkinEthic RHE model	In vitro	ESAC (2008)		EU test method B.46 in COM regulation 440/2008/EC	OECD TG 439 (2010)
Skin sensitization
Reduced LLNA	In vivo	ESAC (2007)	ICCVAM (2009)
Local lymph node assay (LLNA)	In vivo	ICCVAM (1999)	ESAC (1999)		OECD TG 429 (2002), (2010)
Nonradiolabelled LLNA: DA	In vivo	ICCVAM (2009)6	JaCVAM (2008)		OECD TG 422A (2010)
LLNA: BrdU-ELISA	In vivo	ICCVAM (2009)6			OECD TG 422B (2010)
Vaccine potency
ELISA for erysipelas vaccines batch potency testing	In vitro	ESAC (2002)		EDQM/European Pharmacopeia
ELISA for human tetanus vaccines batch potency testing	In vitro	ESAC (2000)		EDQM/European Pharmacopeia
Toxin binding inhibition test for human tetanus vaccines batch potency testing	In vitro	ESAC (2000)		EDQM/European Pharmacopeia

All in vitro and ex vivo methods listed; in vivo methods proposed to reduce or refine animal use also listed

Replaces animal use for initial dose setting, but in vivo test required to complete assessment

TA assay is in process of being formally validated, but included here because of OECD TG

Subject to product-specific validation to demonstrate equivalence to the rabbit pyrogen test (RPT)

Only positive test results accepted in the 2007 endorsement

ICCVAM recommendations being finalized

Conclusion

A number of validated and pre-validated methods exist that can be used as partial or full replacements of animal experiments (e.g. genotoxicity, testing for local toxicity effects as skin corrosion, irritation, quality control of biologicals, production of monoclonal antibodies, safety testing of final cosmetic products).

As proven by several international validation studies, alternative methods have potential to reduce the number of test animals needed for experiments or even replace the whole animal test. Testing strategies combining in vitro, ex vivo and in silico methods could be successful for areas where a single alternative method may currently be failing.

When developing alternative methods for more complex toxicity endpoints, it will be necessary to investigate the toxicology pathways and mechanisms of toxic action. At the same time, we will need to reconsider the predictive ability of the traditional animal tests and their concordance with effects observed in man. These considerations will greatly enhance our ability to produce relevant and reliable alternative methods for prediction of human health effects.